Aerpio Pharmaceuticals Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aerpio Pharmaceuticals stock.
View analyst ratings for Aerpio Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Aerpio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerpio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Aerpio Pharmaceuticals saw a drop in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a drop of 18.3% from the March 15th total of 1,210,000 shares. Based on an average trading volume of 2,030,000 shares, the short-interest ratio is currently 0.5 days. Approximately 2.5% of the company's stock are sold short.
View Aerpio Pharmaceuticals' Short Interest.

Aerpio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Aerpio Pharmaceuticals.

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) announced its quarterly earnings results on Wednesday, March, 10th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03.
View Aerpio Pharmaceuticals' earnings history.

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARPO stock has increased by 135.2% and is now trading at $1.27.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued twelve-month price objectives for Aerpio Pharmaceuticals' shares. Their forecasts range from $1.50 to $4.00. On average, they anticipate Aerpio Pharmaceuticals' stock price to reach $2.75 in the next year. This suggests a possible upside of 116.5% from the stock's current price.
View analysts' price targets for Aerpio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aerpio Pharmaceuticals include 9 Meters Biopharma (NMTR), Ovid Therapeutics (OVID), Xeris Pharmaceuticals (XERS), Atossa Therapeutics (ATOS), Immutep (IMMP), Larimar Therapeutics (LRMR), MediciNova (MNOV), Iterum Therapeutics (ITRM), BioVie (BIVI), Corbus Pharmaceuticals (CRBP), Neptune Wellness Solutions (NEPT), 180 Life Sciences (ATNF), Checkpoint Therapeutics (CKPT), Lannett (LCI) and PLx Pharma (PLXP).
View all of ARPO's competitors.

Aerpio Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARPO."

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARPO stock can currently be purchased for approximately $1.27.

Aerpio Pharmaceuticals has a market capitalization of $60.09 million and generates $20.16 million in revenue each year. The company earns $-23,270,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

Aerpio Pharmaceuticals employs 12 workers across the globe.

The official website for Aerpio Pharmaceuticals is www.aerpio.com.

Aerpio Pharmaceuticals is headquartered at 9987 CARVER ROAD, CINCINNATI OH, 45242.

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513 985 1920 or via email at [email protected]